Quarterly filings was published on August 19th and with that they finally wrote about CVRs, milestone payments shareholders can get
**Chemomab shareholders** will receive contingent value rights (CVRs), providing
the opportunity to **receive future payments of $10 million upon FDA approval of nebokitug for any indication** and **$40 million if Chemomab’s PSC program advances to a Phase 3 clinical trial** or if there is a disposition of nebokitug in the indication of PSC which may be settled in cash, stock or a
combination thereof, at Chemomab Parent’s election, in each case subject to the terms and conditions of the CVR agreement"
And additionally, they submitted the S-4 confidentally to SEC to kickstart the merger process with Scipher Medicine, since they are aiming at a Q4 close for merger and these SEC reviews takes time.
Next catalyst will be the company publishing the S-4 when SEC have cleared it, and we can get the shareholder vote.
Only a month to go until we are officially in Q4, time is ticking.